Login to Your Account

Clinic Roundup

Thursday, April 28, 2011
• BioInvent International AB, of Lund, Sweden, and ThromboGenics NV, of Leuven, Belgium, dosed their first patient in a Phase IIb trial of TB-402 (anti-factor VIII) for thromboembolism after hip surgery. The trial will enroll 600 patients and compare two dose levels of the drug with rivaroxaban. Results are expected in the second half of 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription